Form 4: Amneal Co-CEO Patel Reports Significant Stock Vesting

Amneal Pharmaceuticals' President and Co-CEO, Chirag K. Patel, reported the vesting of over 886,000 shares of Class A Common Stock, including performance-based units that achieved a 200% vesting threshold.

Summary

• Chirag K. Patel, President & Co-CEO of Amneal Pharmaceuticals, Inc. (AMRX), reported multiple transactions involving the vesting of restricted stock units (RSUs) and performance-based restricted stock units (PBRSUs).
• On March 3, 2026, 59,931 shares of Class A Common Stock vested from RSUs, and 15,616 shares were withheld for tax obligations at a price of $13.31 per share.
• Also on March 3, 2026, 733,944 shares of Class A Common Stock vested from performance-based RSUs, and 297,537 shares were withheld for tax obligations at a price of $13.31 per share.
• The performance-based RSUs, granted on March 3, 2023, achieved a 200% vesting threshold based on the Issuer's Class A Common Stock reaching certain average closing prices over a three-year period.
• On March 4, 2026, 92,593 shares of Class A Common Stock vested from RSUs, and 37,825 shares were withheld for tax obligations at a price of $13.30 per share.
• Following these transactions, Mr. Patel directly beneficially owns 1,393,470 shares of Class A Common Stock and indirectly owns 21,269,420 shares through family trusts.
• Remaining derivative securities include 179,795 restricted stock units from a March 3, 2025 grant and 185,185 restricted stock units from a March 4, 2024 grant.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a positive indicator, reflecting strong stock performance that led to the maximum payout for performance-based restricted stock units, aligning executive incentives with shareholder value creation.

Positives

• Significant vesting of 886,468 shares of Class A Common Stock (59,931 + 733,944 + 92,593) for Chirag K. Patel, indicating long-term incentive plan payouts.
• Performance-based restricted stock units achieved a 200% vesting threshold, demonstrating strong company performance relative to specific stock price targets over a three-year period (March 3, 2023 March 3, 2026).
• The Co-CEO's direct beneficial ownership increased to 1,393,470 shares, reinforcing alignment with shareholder interests.

Negatives

• A total of 350,978 shares (15,616 + 297,537 + 37,825) were disposed of to cover tax withholding obligations, which represents a reduction in the net shares received by the executive.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that executive compensation tied to performance-based equity awards, such as the 200% vesting of performance-based RSUs reported by Amneal's Co-CEO, is a common practice in the pharmaceutical industry. This structure aims to align executive incentives with long-term shareholder value creation, particularly through stock price appreciation, which was a key factor in these awards.

Comparison to Industry Standards

• StockSavvy.ai observes that the 200% vesting of performance-based restricted stock units for Amneal's Co-CEO, based on stock price performance, is a strong indicator of the company's stock achieving significant targets. This level of payout is comparable to high-performing executives in the biotech and pharmaceutical sectors where equity incentives are often heavily weighted towards market-based conditions.
• For instance, similar performance-based payouts have been seen at companies like Moderna during its growth phase or certain large-cap pharma companies exceeding market expectations, where executive compensation directly reflects substantial shareholder returns.

Stakeholder Impact

• Shareholders: The vesting of performance-based RSUs at 200% suggests strong stock performance, which is beneficial for shareholders. The increased direct ownership by the Co-CEO also aligns his interests with shareholders.
• Employees: The successful vesting of executive equity awards can signal a healthy company performance, potentially boosting employee morale and confidence.

Next Steps

• Continued vesting of remaining restricted stock units from grants on March 3, 2025, and March 4, 2024, in four equal installments beginning on their respective first anniversaries.

Key Dates

Recommendation

The significant vesting of performance-based restricted stock units at 200% indicates that Amneal Pharmaceuticals' stock has achieved substantial price targets over a three-year period. This strong performance, coupled with the Co-CEO's increased direct ownership, suggests robust company health and strong alignment of management incentives with shareholder value, making it an attractive 'buy' for seasoned investors.

Keywords

Amneal Pharmaceuticals, AMRX, Chirag K. Patel, Form 4, SEC filing, insider transaction, restricted stock units, performance-based RSUs, stock vesting, executive compensation, beneficial ownership, pharmaceutical industry